Neurogene Shares Are Trading Lower. The Company Announced That the First Patient in Cohort 2 Received High-dose NGN-401 Gene Therapy in the Phase 1/2 Trial for Female Pediatric Patients With Rett Syndrome.
Neurogene Shares Are Trading Lower. The Company Announced That the First Patient in Cohort 2 Received High-dose NGN-401 Gene Therapy in the Phase 1/2 Trial for Female Pediatric Patients With Rett Syndrome.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.